

Non-Small-Cell Lung Carcinoma (NSCLC) - Pipeline Insight, 2021

<https://marketpublishers.com/r/N24C32D9EC4EN.html>

Date: February 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: N24C32D9EC4EN

Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Non-Small-Cell Lung Carcinoma (NSCLC) - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Non-Small-Cell Lung Carcinoma (NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Non-Small-Cell Lung Carcinoma (NSCLC) Understanding

Non-Small-Cell Lung Carcinoma (NSCLC): Overview

Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small-cell lung carcinoma (SCLC) and accounts for about 85% of all lung cancers. There are three kinds of NSCLC tumors: a) Adenocarcinoma starts in cells inside air sacs that make mucus and other substances, often in the outer parts of your lungs. It's the most common kind of lung cancer among both smokers and nonsmokers and people under 45. It often grows more slowly than other lung cancers. b) Squamous cell lung carcinoma starts in cells that line the inner airways of the lungs. About a quarter of lung cancers are this kind. c) Large cell (undifferentiated) carcinoma grows and spreads

more quickly. That can make it tougher to treat. It's about 10% of lung cancers. An effective treatment for non-small cell adenocarcinoma depends on the cancer's stage. Surgery to remove all or only part of the lung is usually required if the cancer hasn't spread.

"Non-Small-Cell Lung Carcinoma (NSCLC)- Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Non-Small-Cell Lung Carcinoma (NSCLC) pipeline landscape is provided which includes the disease overview and Non-Small-Cell Lung Carcinoma (NSCLC) treatment guidelines. The assessment part of the report embraces, in depth Non-Small-Cell Lung Carcinoma (NSCLC) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Non-Small-Cell Lung Carcinoma (NSCLC) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Non-Small-Cell Lung Carcinoma (NSCLC) R&D. The therapies under development are focused on novel approaches to treat/improve Non-Small-Cell Lung Carcinoma (NSCLC).

Non-Small-Cell Lung Carcinoma (NSCLC) Emerging Drugs Chapters

This segment of the Non-Small-Cell Lung Carcinoma (NSCLC) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Non-Small-Cell Lung Carcinoma (NSCLC) Emerging Drugs

AMG 510: Amgen

AMG 510 is being developed by Amgen. Phase 1 clinical trials were completed in late 2020. Because the G12C KRAS mutation is relatively common in some cancer types,

14% of non-small-cell lung cancer adenocarcinoma patients and 5% of colorectal cancer patients, and AMG 510 is the first drug candidate to target this mutation, there have been high expectations for the drug. The Food and Drug Administration has granted a fast track designation to AMG 510 for the treatment of metastatic non-small-cell lung carcinoma with the G12C KRAS mutation. The drug is in preregistration stage for the treatment of NSCLC.

CMP 001: Cytos Biotechnology

CMP 001 is a short piece of DNA, called an oligonucleotide that Checkmate designed to mimic the DNA of bacteria. It encapsulated the DNA in noninfectious virus-like particles, or VLPs. The company created CMP-001 to be administered directly to a tumor. When this occurs, the immune system sees VLPs as foreign. It generates immune cells called antigen presenting cells that release the DNA from the VLPs. CMP 001 is in phase 1 of clinical trials for the treatment of non-small cell lung cancer.

Further product details are provided in the report.....

Non-Small-Cell Lung Carcinoma (NSCLC): Therapeutic Assessment

This segment of the report provides insights about the different Non-Small-Cell Lung Carcinoma (NSCLC) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Non-Small-Cell Lung Carcinoma (NSCLC)

There are approx. 10+ key companies which are developing the therapies for Non-Small-Cell Lung Carcinoma (NSCLC). The companies which have their Non-Small-Cell Lung Carcinoma (NSCLC) drug candidates in the mid to advanced stage, i.e. Phase I include, Amgen.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II and Phase I/II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Non-Small-Cell Lung Carcinoma (NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Subcutaneous

Intravenous

Oral

Parenteral

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Small molecules

Peptides

Polymer

Gene Therapy

Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Non-Small-Cell Lung Carcinoma (NSCLC): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Non-Small-Cell Lung Carcinoma (NSCLC) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Non-Small-Cell Lung Carcinoma (NSCLC) drugs.

Non-Small-Cell Lung Carcinoma (NSCLC) Report Insights

- Non-Small-Cell Lung Carcinoma (NSCLC) Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Non-Small-Cell Lung Carcinoma (NSCLC) Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Non-Small-Cell Lung Carcinoma (NSCLC) drugs?

How many Non-Small-Cell Lung Carcinoma (NSCLC) drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Non-Small-Cell Lung Carcinoma (NSCLC)?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Non-Small-Cell Lung Carcinoma (NSCLC) therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Non-Small-Cell Lung Carcinoma (NSCLC) and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Amgen

Cytos Biotechnology

Quriient Co

Novartis

Janssen Pharmaceuticals

Sanofi

ARIAD Pharmaceuticals

AbbVie

Key Products

AMG 510

CMP 001

Q-702

EGF-816

JNJ-6372

SAR408701

TAK-788

Veliparib

Contents

Introduction

Executive Summary

Non-Small-Cell Lung Carcinoma (NSCLC): Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Non-Small-Cell Lung Carcinoma (NSCLC) – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Non-Small-Cell Lung Carcinoma (NSCLC) companies' collaborations, Licensing,
Acquisition -Deal Value Trends

Non-Small-Cell Lung Carcinoma (NSCLC) Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Pre Registration)

Comparative Analysis

AMG 510: Amgen

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

CMP 001: Cytos Biotechnology

Product Description

Research and Development

Product Development Activities

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Non-Small-Cell Lung Carcinoma (NSCLC) Key Companies

Non-Small-Cell Lung Carcinoma (NSCLC) Key Products

Non-Small-Cell Lung Carcinoma (NSCLC)- Unmet Needs

Non-Small-Cell Lung Carcinoma (NSCLC)- Market Drivers and Barriers

Non-Small-Cell Lung Carcinoma (NSCLC)- Future Perspectives and Conclusion

Non-Small-Cell Lung Carcinoma (NSCLC) Analyst Views

Non-Small-Cell Lung Carcinoma (NSCLC) Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Non-Small-Cell Lung Carcinoma (NSCLC)

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Non-Small-Cell Lung Carcinoma (NSCLC)

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Non-Small-Cell Lung Carcinoma (NSCLC) - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/N24C32D9EC4EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N24C32D9EC4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970